Lexicon Pharmaceuticals, Inc. (LXRX) Flies On Cancer Drug Study Results; Hedge Funds Saw This Coming
Shares of Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals Inc. (LXRX)
Market is closed
News
- First
- << Previous
- 31 - 40
- Next >>
Nektar Therapeutics (NKTR): Insiders Aren't Crazy About It But Hedge Funds Love It
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Acorda Therapeutics Inc (ACOR): Insiders Aren't Crazy About It But Hedge Funds Love It
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age.
PDL BioPharma Inc. (PDLI): Hedge Fund and Insider Sentiment Unchanged, What Should You Do?
In the eyes of many market players, hedge funds are seen as overrated, old investment tools of a period lost to current times.
Santarus, Inc. (SNTS): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.
Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Lexicon Pharmaceuticals, Inc. (LXRX), Pfizer Inc. (PFE), GlaxoSmithKline plc (ADR) (GSK): Why Clinical Trials Fail
Drugs fail their clinical trials for all kinds of reasons. Sometimes, it's related to efficacy; sometimes, it's safety related.
What Hedge Funds Think About VIVUS, Inc. (VVUS)
In the 21st century investor’s toolkit, there are dozens of metrics investors can use to track Mr. Market. A couple of the most underrated are hedge fund and insider trading movement.
Lexicon Pharmaceuticals, Inc. (LXRX), Merck & Co., Inc. (MRK): The Worst-Performing Biotech Stocks of the Last Decade
Suppose we filled a jar with slips of paper with the names of biotech companies that have been around for at least 10 years and with a market cap of at $500 million or more written on them.
Lexicon Pharmaceuticals, Inc. (LXRX): Insiders Aren't Crazy About It
In the 21st century investor’s toolkit, there are a multitude of metrics investors can use to monitor stocks. A duo of the best are hedge fund and insider trading activity.
- First
- << Previous
- 31 - 40
- Next >>
Billionaire Hedge Funds
